Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

44.24 -0.58 (-1.28%)
Streaming Delayed Price Updated: 11:22 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast ↗
 
Via Benzinga
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Present at Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Xenon Reports Third Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Insights into Xenon Pharmaceuticals's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Xenon to Report Q3 2025 Financial Results on November 3, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Appointment of Tucker Kelly as Chief Financial Officer
Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Design Therapeutics Appoints Justin Gover to Board of Directors
From Design Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Reports Second Quarter 2025 Financial Results & Business Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon to Report Q2 2025 Financial Results on August 11, 2025
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.